SI9300514A - Immunopotentiatory agent and physiologically acceptable salts thereof - Google Patents

Immunopotentiatory agent and physiologically acceptable salts thereof Download PDF

Info

Publication number
SI9300514A
SI9300514A SI9300514A SI9300514A SI9300514A SI 9300514 A SI9300514 A SI 9300514A SI 9300514 A SI9300514 A SI 9300514A SI 9300514 A SI9300514 A SI 9300514A SI 9300514 A SI9300514 A SI 9300514A
Authority
SI
Slovenia
Prior art keywords
physiologically acceptable
compound
group
acceptable salt
hydrogen
Prior art date
Application number
SI9300514A
Other languages
English (en)
Slovenian (sl)
Inventor
John Richard Rhodes
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220715A external-priority patent/GB9220715D0/en
Priority claimed from GB929226874A external-priority patent/GB9226874D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SI9300514A publication Critical patent/SI9300514A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI9300514A 1992-10-01 1993-09-30 Immunopotentiatory agent and physiologically acceptable salts thereof SI9300514A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929220715A GB9220715D0 (en) 1992-10-01 1992-10-01 Immunopotentiatory agent and physiologically acceptable salts thereof
GB929226874A GB9226874D0 (en) 1992-12-23 1992-12-23 Immunopotentiatory agents and physiologically acceptable salts thereof

Publications (1)

Publication Number Publication Date
SI9300514A true SI9300514A (en) 1994-06-30

Family

ID=26301715

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300514A SI9300514A (en) 1992-10-01 1993-09-30 Immunopotentiatory agent and physiologically acceptable salts thereof

Country Status (24)

Country Link
US (1) US5508310A (fr)
EP (3) EP0609606B1 (fr)
JP (2) JPH07504204A (fr)
KR (1) KR100348775B1 (fr)
CN (1) CN1213746C (fr)
AT (1) ATE146075T1 (fr)
AU (1) AU676491B2 (fr)
CA (1) CA2124677C (fr)
CZ (1) CZ132794A3 (fr)
DE (1) DE69306545T2 (fr)
DK (1) DK0609606T3 (fr)
ES (1) ES2096215T3 (fr)
GR (1) GR3022541T3 (fr)
HR (1) HRP931243A2 (fr)
HU (1) HUT70482A (fr)
IL (1) IL107157A0 (fr)
MX (1) MX9306079A (fr)
NZ (1) NZ256110A (fr)
RU (1) RU94028670A (fr)
SG (1) SG48993A1 (fr)
SI (1) SI9300514A (fr)
SK (1) SK65294A3 (fr)
WO (1) WO1994007479A2 (fr)
YU (1) YU62793A (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005836A2 (fr) * 1994-08-25 1996-02-29 Medical University Of South Carolina Procedes de traitement de symptomes dus au froid au moyen de la pentoxifylline
GB9601544D0 (en) 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
KR100578317B1 (ko) * 1997-05-20 2006-05-11 갈레니카 파마슈티칼스 인크. 면역보강성 및 면역자극 활성을 갖는 트리테르펜 사포닌유사체
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
IL135148A0 (en) * 1997-10-03 2001-05-20 Galenica Pharmaceuticals Inc A polysaccharide conjugate and pharmaceutical compositions containing the same
WO2000009075A2 (fr) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Saponines modifiees chimiquement et leur utilisation comme adjuvants
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
US6939896B2 (en) * 1999-12-21 2005-09-06 Astrazeneca Ab Cd45 inhibitors
ATE308512T1 (de) * 1999-12-21 2005-11-15 Cd45 inhibitoren
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
JP2003528068A (ja) * 2000-03-17 2003-09-24 コリクサ コーポレイション 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
US7033594B2 (en) 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
WO2001076626A2 (fr) * 2000-04-11 2001-10-18 Galenica Pharmaceuticals, Inc. Derives de cetone et d'aldehyde aromatiqueslipophiles et utilisation de ceux-ci en tant qu'immunostimulants et adjuvants
WO2002087424A2 (fr) * 2001-05-02 2002-11-07 Purdue Research Foundation Traitement et diagnostic de maladies associees aux macrophages
ES2338305T3 (es) * 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
US8246969B2 (en) * 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) * 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2004028470A2 (fr) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Therapie prophylactique a l'acide docosahexaenoique pour patients atteints d'inflammation subclinique
EP1622554A4 (fr) * 2003-05-15 2008-01-02 Bioform Medical Inc Compositions contenant un melange d'un agent pharmaceutique ou d'un agent cosmetique et d'un aldehyde aromatique de support de groupe oxy
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2007092299A2 (fr) * 2006-02-03 2007-08-16 Purdue Research Foundation Conjugués ciblés et radiation
EP2222328A4 (fr) * 2007-11-15 2013-06-05 Endocyte Inc Procédé d'administration de conjugués
SG10201602752XA (en) 2011-01-07 2016-05-30 Allergan Inc Melanin modification compositions and methods of use
WO2016144635A1 (fr) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Méthode de traitement d'un cancer lié à une mutation ras
MY181892A (en) 2015-07-13 2021-01-12 Beyondspring Pharmaceuticals Inc Plinabulin compositions
SG11201806583XA (en) * 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54126731A (en) * 1978-03-20 1979-10-02 Rikagaku Kenkyusho Carcinostatic agent
JPS5545658A (en) * 1978-09-28 1980-03-31 Rikagaku Kenkyusho Carcinostatic agent
JPS5569510A (en) * 1978-11-16 1980-05-26 Mitsubishi Chem Ind Ltd Carcinostatic agent
EP0054924B1 (fr) * 1980-12-18 1986-08-06 The Wellcome Foundation Limited Composés pharmaceutiques, leurs procédés de fabrication et leur utilisation
LU85365A1 (de) * 1984-05-16 1986-01-29 Chimicasa Gmbh Verfahren und praeparat zur stimulierung des immunsystems
DE3431236A1 (de) * 1984-08-24 1986-02-27 Carnivora-Deutschland GmbH, 7109 Jagsthausen Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
DE3528709A1 (de) * 1985-08-09 1987-02-19 Schleicher Peter Mundpflegemittel
JPS63264409A (ja) * 1988-01-13 1988-11-01 Rikagaku Kenkyusho 制癌剤
JPH03254007A (ja) * 1990-03-01 1991-11-13 Tir Syst Ltd 非吸収性で且つ透過率が可変のカバーを有した照明装置
GB9018061D0 (en) * 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
EP0499015A1 (fr) * 1991-02-15 1992-08-19 Fockerman, Jasmine Dérivés benzopyrannephénoliques pour utilisation comme agents bactériostatiques, antivirals et immunostimulants

Also Published As

Publication number Publication date
EP0614357A1 (fr) 1994-09-14
HUT70482A (en) 1995-10-30
MX9306079A (es) 1994-06-30
WO1994007479A3 (fr) 1994-07-21
CN1213746C (zh) 2005-08-10
KR100348775B1 (ko) 2003-02-11
GR3022541T3 (en) 1997-05-31
AU4831193A (en) 1994-04-26
YU62793A (sh) 1998-05-15
RU94028670A (ru) 1996-05-20
DE69306545D1 (de) 1997-01-23
EP0678298A2 (fr) 1995-10-25
ES2096215T3 (es) 1997-03-01
WO1994007479A2 (fr) 1994-04-14
CA2124677A1 (fr) 1994-04-14
CA2124677C (fr) 2008-09-09
ATE146075T1 (de) 1996-12-15
SK65294A3 (en) 1995-03-08
IL107157A0 (en) 1993-12-28
HU9401631D0 (en) 1994-08-29
JPH072660A (ja) 1995-01-06
DE69306545T2 (de) 1997-04-03
CZ132794A3 (en) 1995-02-15
JPH07504204A (ja) 1995-05-11
JP3717950B2 (ja) 2005-11-16
EP0609606B1 (fr) 1996-12-11
AU676491B2 (en) 1997-03-13
US5508310A (en) 1996-04-16
EP0609606A1 (fr) 1994-08-10
NZ256110A (en) 1997-07-27
SG48993A1 (en) 1998-05-18
DK0609606T3 (fr) 1997-03-17
HRP931243A2 (en) 1995-12-31
CN1091005A (zh) 1994-08-24
EP0678298A3 (fr) 1996-05-29

Similar Documents

Publication Publication Date Title
SI9300514A (en) Immunopotentiatory agent and physiologically acceptable salts thereof
US6197743B1 (en) Compositions and methods for the treatment of viral disorders
AU686706B2 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
CA2294247C (fr) Amelioration au moyen d'antioxydants de la therapie destinee aux etats d'hyperproliferation
CA2263675C (fr) Composition contenant un agent inducteur ainsi qu'un agent antiviral et destinees au traitement de troubles cellulaires, sanguins et viraux
IE57158B1 (en) Liquid formulations of nimodipine,and a process for their preparation
JP2002523378A (ja) Ｈ２−レセプターアゴニストおよび他のｔ−細胞活性化薬剤を用いたｔ−細胞（ｃｄ４＋およびｃｄ８＋）の活性化および保護
KR20180064438A (ko) Ｎａｓｈ-연관 간암의 치료를 위한 ｅｐ4 수용체 길항제의 용도
US5872151A (en) Immunopotentiatory agents and physiologically acceptable salts thereof
US5958980A (en) Immunopotentiatory agent and physiologically acceptable salts thereof
US6096786A (en) Immunopotentiatory agent and physiologically acceptable salts thereof
JP2002326934A (ja) ピロール誘導体を使用するための方法、キット及び組成物
WO2021197333A1 (fr) Association pharmaceutique et son utilisation
WO1997002822A1 (fr) Medicament destine a soigner les affections du cerveau
JPH0374372A (ja) ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
AU785322B2 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
WO2022076683A1 (fr) Méthodes de traitement d'une infection à coronavirus à l'aide d'acide obéticholique
JPS58174324A (ja) 線溶促進剤
JPH04506517A (ja) ３，３―ジ置換インドリンの鼻腔内投与